| Stage | HLIO | % of rev | PH | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $232M | 100.00% | $5.8B | 100.00% | PH ×24.82 |
| Gross profit | $80M | 34.58% | $2.2B | 39.04% | PH +4.5pp |
| Operating income | $33M | 14.01% | $1.4B | 23.86% | PH +9.8pp |
| Pre-tax income | $28M | 12.12% | $1.3B | 23.28% | PH +11.2pp |
| Net income | $22M | 9.44% | $1.1B | 18.97% | PH +9.5pp |
| Stage | HLIO | PH | Gap · A − B |
|---|---|---|---|
| Revenue | $232M100.00% | $5.8B100.00% | PH ×24.82 |
| Gross profit | 34.58%$80M | 39.04%$2.2B | PH +4.5pp |
| Operating income | 14.01%$33M | 23.86%$1.4B | PH +9.8pp |
| Pre-tax income | 12.12%$28M | 23.28%$1.3B | PH +11.2pp |
| Net income |
| 9.44%$22M |
| 18.97%$1.1B |
| PH +9.5pp |
None
No disclosed counterparties: HLIO.